157 related articles for article (PubMed ID: 24114662)
1. PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α.
Qu Z; Wang S; Teng R; Yi X
Mol Cell Biochem; 2014 Jan; 386(1-2):135-42. PubMed ID: 24114662
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
3. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale Ş; Korcum AF; Dündar E; Erin N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
6. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
7. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
8. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
Soudan H; Saeed H; Eldemellawy M; Shalaby M; Hassan M; Elkewedi M; El-Nikhely N
Acta Biochim Pol; 2020 Dec; 67(4):561-570. PubMed ID: 33319549
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
11. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.
Anwar MM; Shalaby M; Embaby AM; Saeed H; Agwa MM; Hussein A
Sci Rep; 2020 Sep; 10(1):14706. PubMed ID: 32895397
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
[TBL] [Abstract][Full Text] [Related]
13. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.
Lisi L; McGuire S; Sharp A; Chiosis G; Navarra P; Feinstein DL; Dello Russo C
J Neuroimmunol; 2013 Feb; 255(1-2):1-7. PubMed ID: 23123171
[TBL] [Abstract][Full Text] [Related]
14. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).
Liu M; Wang J; Wu X; Wang E; Baptista D; Scott B; Liu P
J Pharm Biomed Anal; 2014 Feb; 89():34-41. PubMed ID: 24252723
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway.
Qu Z; Dong H; Xu X; Feng W; Yi X
Diagn Pathol; 2013 May; 8():70. PubMed ID: 23635099
[TBL] [Abstract][Full Text] [Related]
16. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
17. Enterovirus 71 2C protein inhibits TNF-α-mediated activation of NF-κB by suppressing IκB kinase β phosphorylation.
Zheng Z; Li H; Zhang Z; Meng J; Mao D; Bai B; Lu B; Mao P; Hu Q; Wang H
J Immunol; 2011 Sep; 187(5):2202-12. PubMed ID: 21810613
[TBL] [Abstract][Full Text] [Related]
18. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.
Tse AK; Wan CK; Shen XL; Yang M; Fong WF
Biochem Pharmacol; 2005 Nov; 70(10):1443-57. PubMed ID: 16181613
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation.
Funakoshi-Tago M; Tanabe S; Tago K; Itoh H; Mashino T; Sonoda Y; Kasahara T
Mol Pharmacol; 2009 Oct; 76(4):745-53. PubMed ID: 19592502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]